This report provides a comprehensive analysis of the global Pseudorabies Virus Vaccine market, projecting steady growth from 2025 through 2032. It examines various product types, including live attenuated, inactivated, and gene-deleted marker vaccines, across diverse strain platforms and applications in swine farming. Key market drivers include the expansion of intensive pig production and rising biosecurity needs, while competition is shifting toward integrated prevention solutions. The study offers detailed regional insights and competitive intelligence to identify emerging opportunities within this mature veterinary biological segment.

Market Overview

The global Pseudorabies Virus Vaccine market is projected to grow from US$ 165 million in 2025 to US$ 253 million in 2032, representing a compound annual growth rate (CAGR) of 6.3% from 2026 to 2032.

Product Definition & Utility

Pseudorabies Virus Vaccine is a veterinary biological product designed to protect swine populations against pseudorabies virus infection.

• Targeted Livestock: Piglets, fattening pigs, replacement gilts, sows, and boars.
• Key Benefits: Reduction of clinical disease, mortality, reproductive losses, and virus shedding within swine herds.

Industry Value Chain & Technical Specifications

Product Scope & Forms

• Vaccine Types: Live attenuated vaccines, inactivated vaccines, gene-deleted marker vaccines, and combination vaccines containing pseudorabies virus antigens.
• Primary Product Forms: Freeze-dried live vaccines and oil-emulsion inactivated vaccines.
• Strain Platforms: The most common and highest-volume platforms include Bartha-K61, HB98, and C strain.

Upstream Inputs

• Production strains
• Cell substrates
• Culture media
• Adjuvants
• Stabilizers
• Freeze-drying protectants
• Inactivating agents
• Packaging materials
• Cold-chain packaging materials

Downstream Customers

• Large-scale swine farming groups
• Breeding farms
• Commercial pig farms
• Veterinary drug distributors
• Animal disease control bodies

2025 Industry Economic Indicators (Ex-factory Finished Vaccine)

• Global Designed Capacity: Approximately 2.28 billion doses
• Actual Sales Volume: Approximately 1.64 billion doses
• Average Ex-factory ASP: Around USD 0.10 per dose
• Industry Gross Margin: Approximately 46%–61%
• Note on Margins: Differentiated products (marker vaccines, variant-strain inactivated vaccines, and combination vaccines) generally command higher prices and margins compared to conventional live vaccines.

Market Dynamics

Current Market Status

The Pseudorabies Virus Vaccine market is a mature commercial segment within the broader swine vaccine industry. It is characterized by stable baseline immunization demand alongside significant regional variations.

• Asia: China and selected intensive swine-producing regions in Asia serve as the most active demand centers. Demand is driven by large-scale farms focusing on reproductive stability, piglet survival, fattening herd health, and farm-level purification programs.
• Europe & North America: Disease eradication and monitoring systems are more mature, resulting in relatively stable commercial vaccine demand primarily supported by a limited number of multinational animal health companies.
• Overall Outlook: The market is not a high-growth emerging market but rather a stable market driven by routine vaccination, product upgrading, and the demand for higher-quality disease control.

Growth Drivers

• Intensive Farming Expansion: The growth of intensive pig farming operations.
• Disease Prevention Protocols: Normalization of disease prevention and the need for regional herd purification.
• Productivity Requirements: The necessity to improve sow productivity.
• Biosecurity & Monitoring: As producers raise requirements for biosecurity and disease monitoring, the value proposition of suppliers is expanding beyond the product to include immunization program design, antibody monitoring support, purification-route advice, and on-site technical services.
• Regulatory Environment: Stricter regulations and higher quality requirements for veterinary biological products favor suppliers with robust technical capabilities and complete quality systems.

Market Restraints & Challenges

• Economic Volatility: Hog-cycle volatility can impact spending; when farm profitability is weak, small and medium-sized farms may reduce disease-prevention expenditures.
• Market Homogenization: High competition in mainstream strain platforms creates pricing and channel pressure.
• Differentiation Difficulties: Challenges in proving clear product differentiation in a crowded market.
• Development Barriers: New-generation products (marker vaccines, variant-strain inactivated vaccines, and combination products) face long development cycles involving research, registration, field validation, and scaled manufacturing.

Future Trends & Competitive Evolution

Competition is expected to shift from the simple supply of conventional vaccines toward comprehensive prevention solutions tailored to the immunization programs of large-scale swine farms. Key competitive factors will include:

• Strain matching and duration of protection.
• Batch-to-batch consistency.
• Safety and compatibility with other swine vaccines.
• Integrated services (purification support, variant-strain control, and improved immunization efficiency).

Future market concentration is expected to favor companies with broad product portfolios, stable manufacturing quality, strong access to integrated farming groups, and solid technical service capabilities.

Market Segmentation

By Type

• Live Attenuated Vaccine
• Inactivated Vaccine
• Others

By Strain Platform

• Bartha-K61 Strain
• HB98 Strain
• C Strain
• Other

By Dose Pack Size

• Small Pack (Below 20 Doses per Vial)
• Medium Pack (20–50 Doses per Vial)
• Large Pack (Above 50 Doses per Vial)

By Application

• Large-scale Swine Farming Groups
• Breeding Farms
• Animal Disease Control Institutions
• Others

By Geography

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key profiled companies include:

• MSD Animal Health
• Boehringer Ingelheim
• HIPRA
• Ceva Santé Animale
• Wuhan Keqian Biology
• Pulike Biological Engineering
• China Animal Husbandry Industry
• Jinyu Bio-Technology
• Guangdong Winsun Bio-Pharmaceutical
• Huapai Biopharm
• Jilin Zhengye Biological Products
• Sinopharm Yangzhou VAC Biological Engineering
• Sinovet Animal Health
• Jofunhwa Group
• Harbin Weike Biotechnology
• Qilu Animal Health Products
• Harbin Pharmaceutical Group Bio-vaccine
• Qingdao Yebio Bioengineering

Report Scope & Methodology

This research by LP Information, Inc. (LPI) provides a comprehensive analysis of the global Pseudorabies Virus Vaccine landscape. The report covers:

• Past sales data and a total review of global sales in 2025.
• Detailed projections for 2026 through 2032, broken down by region, market sector, and sub-sector (expressed in US$ millions).
• Analysis of key trends: product segmentation, company formation, revenue, market share, latest developments, and M&A activity.
• Strategic analysis of leading global companies regarding portfolios, market entry, market position, and geographic footprints.
• Evaluation of market drivers, trends, and affecting factors using a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs.

Key Questions Addressed

• What is the 10-year outlook for the global Pseudorabies Virus Vaccine market?
• What factors are driving Pseudorabies Virus Vaccine market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Pseudorabies Virus Vaccine market opportunities vary by end market size?
• How does Pseudorabies Virus Vaccine break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Pseudorabies Virus Vaccine Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Pseudorabies Virus Vaccine by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Pseudorabies Virus Vaccine by Country/Region, 2021, 2025 & 2032

  • 2.2 Pseudorabies Virus Vaccine Segment by Type

    • 2.2.1 Live Attenuated Vaccine

    • 2.2.2 Inactivated Vaccine

    • 2.2.3 Others

    • 2.2.4 Pseudorabies Virus Vaccine Sales by Type

      • 2.2.4.1 Global Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
      • 2.2.4.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Type (2021-2026)
      • 2.2.4.3 Global Pseudorabies Virus Vaccine Sale Price by Type (2021-2026)

  • 2.3 Pseudorabies Virus Vaccine Segment by Strain Platform

    • 2.3.1 Bartha-K61 Strain

    • 2.3.2 HB98 Strain

    • 2.3.3 C Strain

    • 2.3.4 Other

    • 2.3.5 Pseudorabies Virus Vaccine Sales by Strain Platform

      • 2.3.5.1 Global Pseudorabies Virus Vaccine Sales Market Share by Strain Platform (2021-2026)
      • 2.3.5.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Strain Platform (2021-2026)
      • 2.3.5.3 Global Pseudorabies Virus Vaccine Sale Price by Strain Platform (2021-2026)

  • 2.4 Pseudorabies Virus Vaccine Segment by Dose Pack Size

    • 2.4.1 Small Pack (Below 20 Doses per Vial)

    • 2.4.2 Medium Pack (20–50 Doses per Vial)

    • 2.4.3 Large Pack (Above 50 Doses per Vial)

    • 2.4.4 Pseudorabies Virus Vaccine Sales by Dose Pack Size

      • 2.4.4.1 Global Pseudorabies Virus Vaccine Sales Market Share by Dose Pack Size (2021-2026)
      • 2.4.4.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)
      • 2.4.4.3 Global Pseudorabies Virus Vaccine Sale Price by Dose Pack Size (2021-2026)

  • 2.5 Pseudorabies Virus Vaccine Segment by Application

    • 2.5.1 Large-scale Swine Farming Groups

    • 2.5.2 Breeding Farms

    • 2.5.3 Animal Disease Control Institutions

    • 2.5.4 Others

    • 2.5.5 Pseudorabies Virus Vaccine Sales by Application

      • 2.5.5.1 Global Pseudorabies Virus Vaccine Sale Market Share by Application (2021-2026)
      • 2.5.5.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Application (2021-2026)
      • 2.5.5.3 Global Pseudorabies Virus Vaccine Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Pseudorabies Virus Vaccine Breakdown Data by Company

    • 3.1.1 Global Pseudorabies Virus Vaccine Annual Sales by Company (2021-2026)

    • 3.1.2 Global Pseudorabies Virus Vaccine Sales Market Share by Company (2021-2026)

  • 3.2 Global Pseudorabies Virus Vaccine Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Pseudorabies Virus Vaccine Revenue by Company (2021-2026)

    • 3.2.2 Global Pseudorabies Virus Vaccine Revenue Market Share by Company (2021-2026)

  • 3.3 Global Pseudorabies Virus Vaccine Sale Price by Company

  • 3.4 Key Manufacturers Pseudorabies Virus Vaccine Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Pseudorabies Virus Vaccine Product Location Distribution

    • 3.4.2 Players Pseudorabies Virus Vaccine Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Pseudorabies Virus Vaccine by Geographic Region

  • 4.1 World Historic Pseudorabies Virus Vaccine Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Pseudorabies Virus Vaccine Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Pseudorabies Virus Vaccine Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Pseudorabies Virus Vaccine Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Pseudorabies Virus Vaccine Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Pseudorabies Virus Vaccine Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Pseudorabies Virus Vaccine Sales Growth

  • 4.4 APAC Pseudorabies Virus Vaccine Sales Growth

  • 4.5 Europe Pseudorabies Virus Vaccine Sales Growth

  • 4.6 Middle East & Africa Pseudorabies Virus Vaccine Sales Growth

• 5 Americas

  • 5.1 Americas Pseudorabies Virus Vaccine Sales by Country

    • 5.1.1 Americas Pseudorabies Virus Vaccine Sales by Country (2021-2026)

    • 5.1.2 Americas Pseudorabies Virus Vaccine Revenue by Country (2021-2026)

  • 5.2 Americas Pseudorabies Virus Vaccine Sales by Type (2021-2026)

  • 5.3 Americas Pseudorabies Virus Vaccine Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Pseudorabies Virus Vaccine Sales by Region

    • 6.1.1 APAC Pseudorabies Virus Vaccine Sales by Region (2021-2026)

    • 6.1.2 APAC Pseudorabies Virus Vaccine Revenue by Region (2021-2026)

  • 6.2 APAC Pseudorabies Virus Vaccine Sales by Type (2021-2026)

  • 6.3 APAC Pseudorabies Virus Vaccine Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Pseudorabies Virus Vaccine by Country

    • 7.1.1 Europe Pseudorabies Virus Vaccine Sales by Country (2021-2026)

    • 7.1.2 Europe Pseudorabies Virus Vaccine Revenue by Country (2021-2026)

  • 7.2 Europe Pseudorabies Virus Vaccine Sales by Type (2021-2026)

  • 7.3 Europe Pseudorabies Virus Vaccine Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Pseudorabies Virus Vaccine by Country

    • 8.1.1 Middle East & Africa Pseudorabies Virus Vaccine Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Pseudorabies Virus Vaccine Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Pseudorabies Virus Vaccine Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Pseudorabies Virus Vaccine Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Pseudorabies Virus Vaccine

  • 10.3 Manufacturing Process Analysis of Pseudorabies Virus Vaccine

  • 10.4 Industry Chain Structure of Pseudorabies Virus Vaccine

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Pseudorabies Virus Vaccine Distributors

  • 11.3 Pseudorabies Virus Vaccine Customer

• 12 World Forecast Review for Pseudorabies Virus Vaccine by Geographic Region

  • 12.1 Global Pseudorabies Virus Vaccine Market Size Forecast by Region

    • 12.1.1 Global Pseudorabies Virus Vaccine Forecast by Region (2027-2032)

    • 12.1.2 Global Pseudorabies Virus Vaccine Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Pseudorabies Virus Vaccine Forecast by Type (2027-2032)

  • 12.7 Global Pseudorabies Virus Vaccine Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 MSD Animal Health

    • 13.1.1 MSD Animal Health Company Information

    • 13.1.2 MSD Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.1.3 MSD Animal Health Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 MSD Animal Health Main Business Overview

    • 13.1.5 MSD Animal Health Latest Developments

  • 13.2 Boehringer Ingelheim

    • 13.2.1 Boehringer Ingelheim Company Information

    • 13.2.2 Boehringer Ingelheim Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.2.3 Boehringer Ingelheim Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 Boehringer Ingelheim Main Business Overview

    • 13.2.5 Boehringer Ingelheim Latest Developments

  • 13.3 HIPRA

    • 13.3.1 HIPRA Company Information

    • 13.3.2 HIPRA Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.3.3 HIPRA Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 HIPRA Main Business Overview

    • 13.3.5 HIPRA Latest Developments

  • 13.4 Ceva Santé Animale

    • 13.4.1 Ceva Santé Animale Company Information

    • 13.4.2 Ceva Santé Animale Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.4.3 Ceva Santé Animale Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 Ceva Santé Animale Main Business Overview

    • 13.4.5 Ceva Santé Animale Latest Developments

  • 13.5 Wuhan Keqian Biology

    • 13.5.1 Wuhan Keqian Biology Company Information

    • 13.5.2 Wuhan Keqian Biology Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.5.3 Wuhan Keqian Biology Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.5.4 Wuhan Keqian Biology Main Business Overview

    • 13.5.5 Wuhan Keqian Biology Latest Developments

  • 13.6 Pulike Biological Engineering

    • 13.6.1 Pulike Biological Engineering Company Information

    • 13.6.2 Pulike Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.6.3 Pulike Biological Engineering Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.6.4 Pulike Biological Engineering Main Business Overview

    • 13.6.5 Pulike Biological Engineering Latest Developments

  • 13.7 China Animal Husbandry Industry

    • 13.7.1 China Animal Husbandry Industry Company Information

    • 13.7.2 China Animal Husbandry Industry Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.7.3 China Animal Husbandry Industry Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.7.4 China Animal Husbandry Industry Main Business Overview

    • 13.7.5 China Animal Husbandry Industry Latest Developments

  • 13.8 Jinyu Bio-Technology

    • 13.8.1 Jinyu Bio-Technology Company Information

    • 13.8.2 Jinyu Bio-Technology Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.8.3 Jinyu Bio-Technology Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.8.4 Jinyu Bio-Technology Main Business Overview

    • 13.8.5 Jinyu Bio-Technology Latest Developments

  • 13.9 Guangdong Winsun Bio-Pharmaceutical

    • 13.9.1 Guangdong Winsun Bio-Pharmaceutical Company Information

    • 13.9.2 Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.9.3 Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.9.4 Guangdong Winsun Bio-Pharmaceutical Main Business Overview

    • 13.9.5 Guangdong Winsun Bio-Pharmaceutical Latest Developments

  • 13.10 Huapai Biopharm

    • 13.10.1 Huapai Biopharm Company Information

    • 13.10.2 Huapai Biopharm Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.10.3 Huapai Biopharm Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.10.4 Huapai Biopharm Main Business Overview

    • 13.10.5 Huapai Biopharm Latest Developments

  • 13.11 Jilin Zhengye Biological Products

    • 13.11.1 Jilin Zhengye Biological Products Company Information

    • 13.11.2 Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.11.3 Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.11.4 Jilin Zhengye Biological Products Main Business Overview

    • 13.11.5 Jilin Zhengye Biological Products Latest Developments

  • 13.12 Sinopharm Yangzhou VAC Biological Engineering

    • 13.12.1 Sinopharm Yangzhou VAC Biological Engineering Company Information

    • 13.12.2 Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.12.3 Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.12.4 Sinopharm Yangzhou VAC Biological Engineering Main Business Overview

    • 13.12.5 Sinopharm Yangzhou VAC Biological Engineering Latest Developments

  • 13.13 Sinovet Animal Health

    • 13.13.1 Sinovet Animal Health Company Information

    • 13.13.2 Sinovet Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.13.3 Sinovet Animal Health Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.13.4 Sinovet Animal Health Main Business Overview

    • 13.13.5 Sinovet Animal Health Latest Developments

  • 13.14 Jofunhwa Group

    • 13.14.1 Jofunhwa Group Company Information

    • 13.14.2 Jofunhwa Group Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.14.3 Jofunhwa Group Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.14.4 Jofunhwa Group Main Business Overview

    • 13.14.5 Jofunhwa Group Latest Developments

  • 13.15 Harbin Weike Biotechnology

    • 13.15.1 Harbin Weike Biotechnology Company Information

    • 13.15.2 Harbin Weike Biotechnology Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.15.3 Harbin Weike Biotechnology Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.15.4 Harbin Weike Biotechnology Main Business Overview

    • 13.15.5 Harbin Weike Biotechnology Latest Developments

  • 13.16 Qilu Animal Health Products

    • 13.16.1 Qilu Animal Health Products Company Information

    • 13.16.2 Qilu Animal Health Products Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.16.3 Qilu Animal Health Products Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.16.4 Qilu Animal Health Products Main Business Overview

    • 13.16.5 Qilu Animal Health Products Latest Developments

  • 13.17 Harbin Pharmaceutical Group Bio-vaccine

    • 13.17.1 Harbin Pharmaceutical Group Bio-vaccine Company Information

    • 13.17.2 Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.17.3 Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.17.4 Harbin Pharmaceutical Group Bio-vaccine Main Business Overview

    • 13.17.5 Harbin Pharmaceutical Group Bio-vaccine Latest Developments

  • 13.18 Qingdao Yebio Bioengineering

    • 13.18.1 Qingdao Yebio Bioengineering Company Information

    • 13.18.2 Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Product Portfolios and Specifications

    • 13.18.3 Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.18.4 Qingdao Yebio Bioengineering Main Business Overview

    • 13.18.5 Qingdao Yebio Bioengineering Latest Developments

• 14 Research Findings and Conclusion